Literature DB >> 16954808

Challenges in pediatric inflammatory bowel disease.

Athos Bousvaros1, Francisco Sylvester, Subra Kugathasan, Eva Szigethy, Claudio Fiocchi, Richard Colletti, Anthony Otley, Devendra Amre, George Ferry, Steven J Czinn, Judy B Splawski, Maria Oliva-Hemker, Jeffrey S Hyams, William A Faubion, Barbara S Kirschner, Marla C Dubinsky.   

Abstract

It is estimated that of the >1 million individuals in the United States with inflammatory bowel disease (IBD), approximately 100,000 are children. IBD that begins in childhood affects the individual at a critical period of growth and development. Children with Crohn's disease and ulcerative colitis may experience complications such as growth failure, school absence, and depression. In addition, because children with IBD have fewer environmental confounders such as smoking, children may be an excellent population to study microbial and immune interactions. Despite these opportunities, the discipline of pediatric IBD investigation is still in its infancy. In September of 2005, a group of investigators with expertise in pediatric IBD met in Boston (Massachusetts) to review the current status of childhood IBD research and to develop research priorities that warranted funding from the Crohn's and Colitis Foundation of America. The group included pediatricians, internists, basic scientists, clinical investigators, and members of the administrative staff and board of the Crohn's and Colitis Foundation of America. The research needs in respective areas were outlined by the heads of 10 focus groups, each with expertise in their respective fields (genetics, psychosocial issues, epidemiology, microbiology, immunology, quality improvement, pharmacogenomics, nutrition, growth and skeletal health, and clinical trials). Before the conference, heads of the research focus groups developed their proposals with experts in the field. At the end of the conference, members of the focus groups and members of the steering committee rated the proposed areas of study in terms of feasibility and importance. It was recommended that the Crohn's and Colitis Foundation of America focus its initial efforts in pediatric IBD in 5 areas: the effects of inflammation on growth and skeletal development, the genetics of early-onset IBD, the development of quality improvement interventions to standardize and improve clinical care of children with IBD, the immunology of childhood IBD, and the diagnosis and treatment of psychosocial sequelae of childhood IBD. At the conclusion of the meeting, investigators discussed the formation of a multicenter collaborative network to advance clinical and basic research in the field.

Entities:  

Mesh:

Year:  2006        PMID: 16954808     DOI: 10.1097/01.mib.0000228358.25364.8b

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  38 in total

1.  Gastrointestinal histopathology in chronic granulomatous disease: a study of 87 patients.

Authors:  Meghna Alimchandani; Jin-Ping Lai; Phyu Phyu Aung; Sajneet Khangura; Natasha Kamal; John I Gallin; Steven M Holland; Harry L Malech; Theo Heller; Markku Miettinen; Martha M Quezado
Journal:  Am J Surg Pathol       Date:  2013-09       Impact factor: 6.394

Review 2.  Quality of health care in the United States: implications for pediatric inflammatory bowel disease.

Authors:  Brendan M Boyle; Lena Palmer; Michael D Kappelman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-09       Impact factor: 2.839

3.  Transferring IBD Patients From Pediatric to Adult Care.

Authors:  George D Ferry
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-11

Review 4.  Role of genetics in pediatric inflammatory bowel disease.

Authors:  David T Okou; Subra Kugathasan
Journal:  Inflamm Bowel Dis       Date:  2014-10       Impact factor: 5.325

5.  A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

6.  Laparoscopic approach for children with inflammatory bowel diseases.

Authors:  Girolamo Mattioli; Alessio Pini-Prato; Arrigo Barabino; Paolo Gandullia; Stefano Avanzini; Edoardo Guida; Valentina Rossi; Luca Pio; Nicola Disma; Leila Mameli; Della Rocca Mirta; Giovanni Montobbio; Vincenzo Jasonni
Journal:  Pediatr Surg Int       Date:  2011-03-27       Impact factor: 1.827

7.  The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function.

Authors:  Dominik Bettenworth; Marion Buyse; Markus Böhm; Rudolf Mennigen; Isabel Czorniak; Klaus Kannengiesser; Thomas Brzoska; Thomas A Luger; Torsten Kucharzik; Wolfram Domschke; Christian Maaser; Andreas Lügering
Journal:  Am J Pathol       Date:  2011-07-08       Impact factor: 4.307

8.  Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease.

Authors:  B Szebeni; G Veres; A Dezsõfi; K Rusai; A Vannay; M Mraz; E Majorova; A Arató
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

9.  Variation in Antibiotic Use for Children Hospitalized With Inflammatory Bowel Disease Exacerbation: A Multicenter Validation Study.

Authors:  Matthew P Kronman; Jeffrey S Gerber; Priya A Prasad; Amanda L Adler; Julie A Bass; Jason G Newland; Kavisha M Shah; Danielle M Zerr; Rui Feng; Susan E Coffin; Theoklis E Zaoutis
Journal:  J Pediatric Infect Dis Soc       Date:  2012-07-03       Impact factor: 3.164

Review 10.  Crohn's disease: a review of current treatment with a focus on biologics.

Authors:  Julián Panés; Fernando Gomollón; Carlos Taxonera; Joaquin Hinojosa; Juan Clofent; Pilar Nos
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.